Jared Gollob - 15 Jul 2024 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Medical Officer
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
15 Jul 2024
Net transactions value
-$1,720,775
Form type
4
Filing time
16 Jul 2024, 18:00:31 UTC
Previous filing
04 Mar 2024
Next filing
03 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $34,226 +16,455 +17% $2.08* 112,195 15 Jul 2024 Direct F1
transaction KYMR Common Stock Sale $742,925 -16,455 -15% $45.15 95,740 15 Jul 2024 Direct F1, F2
transaction KYMR Common Stock Options Exercise $48,142 +23,145 +24% $2.08* 118,885 16 Jul 2024 Direct F1
transaction KYMR Common Stock Sale $605,522 -13,281 -11% $45.59 105,604 16 Jul 2024 Direct F1, F3
transaction KYMR Common Stock Sale $454,696 -9,864 -9.4% $46.10 95,470 16 Jul 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -16,455 -26% $0.000000 46,028 15 Jul 2024 Common Stock 16,455 $2.08 Direct F1, F5
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -23,145 -50% $0.000000 22,883 16 Jul 2024 Common Stock 23,145 $2.08 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.02 to $46.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.02 to $46.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.